Purpose: The assessment of the antifungal activity of 59 new synthesized compounds. We compared the antifungal activity of N,N-phenyl-1,2,3,4-thiatriazole-5-yl-2,4-b-resorcyl-carbothioamide (PTR), of n-3-(1,2,4-dithiazole-5-thione)--reso-rcylcarbothioamide (DTRTA), of N,N-phenyl-1,2,3,4-thiatriazol-5-yl-2,4-b-resorcyl-carbothio-amide (PHARA) against Candida albicans strains in vitro. Material and methods: We evaluated 59 samples of the compounds synthesized at the Department of Chemistry University of Agriculture in Lublin. In the first phase, we tested the selected three samples with the lowest value of MIC - PTR, DTRTA, and PHARA. A reference strain of C. albicans ATCC 10231 and 200 strains of C. albicans isolated from the patients was used. Results: The MIC values of the tested samples fluctuated between 19.6 - 200 mg/L. The tested compounds showed moderate antifungal activity against C. albicans with MIC values of 19.6 mg/L for PTR, 22.0 mg/L for DTRTA, and 19.6 mg/L for PHARA. We found significant (p<0.001) differences between mean MIC values for PTR, DTRTA, PHARA on RPMI medium compared with MIC values on Sabouraud’s and YNB medium. Similar results we found for the reference strains C. albicans ATCC 10231. The reference strain C. albicans ATCC 10231 had enzymatic activity of 14 from 19 hydrolases in the (APIZYM), after exposure PTR number of the active enzymes was 6, after exposure DTRTA – 9, after exposure PHARA – 6, respectively. Isolates of C. albicans from the patients had enzymatic activity of 16 from 19 hydrolases, after exposure PTR number of active enzymes was 11, after exposure DTRTA – 15, and after exposure PHARA - 11. Conclusion: The synthesized compounds PTR, DTRA and PHARA exert a moderate antifungal activity against the C. albicans strains in vitro.